|
Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer Clinical research trials and Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer. Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer  Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
For Condition: Carcinoma, Non-Small-Cell Lung
Status: No longer recruiting
Sponsor(s): Telik ,
Synopsis: The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every three weeks in combination with docetaxel (Taxotere) in the treatment of patients with non-small cell lung cancer that is resistant to platinum-based chemotherapy.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion criteria include: - Histologically confirmed non-small cell bronchogenic carcinoma, including squamous cell carcinoma, undifferentiated carcinoma, adenocarcinoma, mixed (adenocarcinoma with squamous cell carcinoma), bronchoalveolar carcinoma, or large cell carcinoma - Stage IV or Stage IIIB - Progressed during or after first-line therapies with platinum-containing regimens in the advanced or metastatic treatment regimen - At least 18 years of age - Good performance status (ECOG 0 to 1) - Adequate liver, renal, and bone marrow function Exclusion criteria include: - Pregnant or lactating women - Treatment with more than one cytotoxic therapy - Prior radiation to the whole pelvis - Unstable medical conditions such as uncontrolled cardiac arrhythmia - Patients with known history of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80
Total Enrollment: 28
Location and Contact Information:
Cancer Institute Medical Group
Los Angeles, California, 90025
United States
M.D. Anderson Cancer Center
Houston, Texas, 77030
United States
Indiana University Cancer Center
Indianapolis, Indiana, 46202
United States
UCLA Medical Center
Los Angeles, California, 90095
United States
Additional Information:
Study ID Numbers: TLK286.2012;
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00047801
Other Carcinoma, Non-Small-Cell Lung Studies:
1. Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer
2. Comparative Trial of Pivanex and Docetaxel vs Docetaxel Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer
3. ALIMTA plus Carboplatin as Front-Line Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
4. Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
5. A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer
Related Studies:
Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
|
|
|
|
|
|
|
|
